Open access · US-GOV
via ClinicalTrials.gov Clinical trial
PTMDP (Post-translational Modification Derived Products) as Markers of Frailty in Elderly Subjects
Authors not listed
CHU de Reims · 2015
Abstract
Epidemiological data from Europe have shown that around 30% of subjects aged over 65 years of age are pre-frail, and 15% are frail. Recent research has demonstrated that identifying frailty and implementing preventive measures can help to slow cognitive decline. Screening and treating frailty seem to be a good start towards preventing dependency.
On the premise that this frailty is the result of more pronounced tissue alterations in certain elderly subjects, assessment of post-translational modification derived products (PTMDP) represents an innovative evaluation method. These include advanced glycation end-products (AGE), and carbamylation-derived products (homocitrulline). Indeed, the intensity of these modifications increases with ageing, and assessing the products resulting from these alterations could show the existence of differences according to frailty status. This would make it possible to adapt treatment accordingly in elderly subjects.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-16 MST
Cite this
APA
Anonymous. (2015). PTMDP (Post-translational Modification Derived Products) as Markers of Frailty in Elderly Subjects. <em>CHU de Reims</em>. https://clinicaltrials.gov/study/NCT02816580
Vancouver
Anonymous. PTMDP (Post-translational Modification Derived Products) as Markers of Frailty in Elderly Subjects. CHU de Reims. 2015.
BibTeX
@misc{anon2015PTMDPP,
title = {PTMDP (Post-translational Modification Derived Products) as Markers of Frailty in Elderly Subjects},
author = {Anonymous},
journal = {CHU de Reims},
year = {2015},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Springer eBooks 2020
Citation only
Frailty Assessment
The Journal of Frailty & Aging 2016
Citation only
FRAILTY ACROSS AGE GROUPS
Neurotherapeutics 2018
Open access · OA
Inclusion Body Myositis: Update on Pathogenesis and Treatment
Atherosclerosis 2017
Preprint · CC-BY
Atherosclerosis in frailty: Not frailty in atherosclerosis
The American Journal of Cardiology 2016
Citation only
Cardiac Structure and Function and Frailty in Subjects Aged 85 and 86 Years
Abramson Cancer Center at Penn Medicine 2018
Open access · US-GOV